New EMA information for drug development within H2020

The European Medicines Agency (EMA) has updated the set of information it provides to drug developers working within the context of clinical trials funded via Horizon 2020, the EU research funding programme.

EMA’s new guidance provides the project coordinators with a checklist of regulatory issues they should monitor.

Furthermore, EMA provides info on new clinical trial methodologies and regulatory aspects related to trials design.

Finally, EMA reminds all the H2020 projects partners that their scientific advice is available before, during and after the submission of the proposal and the signature of the grant agreement.

For the updated EMA website on H2020, please click here.